# A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

> **NCT07684599** · PHASE3 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 610 (estimated)

## Conditions studied

- Neoplasms, Endometrial

## Interventions

- **DRUG:** Mocertatug rezetecan
- **DRUG:** Dostarlimab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07684599
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-03
- **Primary completion:** 2029-07-23
- **Final completion:** 2031-09-18
- **Target enrollment:** 610 (ESTIMATED)
- **Last updated:** 2026-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684599, "A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07684599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*